Trials / Completed
CompletedNCT01366014
A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study, involving a 4-week treatment period, designed to test the ability of investigational study drug ARRY-371797 to reduce pain in patients with moderate to severe pain due to osteoarthritis (OA) of the knee, and to further evaluate the drug's safety. Approximately 150 patients from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-371797, p38 inhibitor; oral | multiple dose, single schedule |
| DRUG | Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral | multiple dose, single schedule |
| DRUG | Placebo; oral | matching placebo |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-06-03
- Last updated
- 2020-10-14
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01366014. Inclusion in this directory is not an endorsement.